Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 114 participants.
Also called NCT06712030
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 114 participants
- Registry
-
NCT06712030 -
2024-515661-34-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06712030. Randomized; single masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
- Acronym
- SAVA-TTR
- Condition
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Intervention (Drug)
- Sacubitril / Valsartan
- Lead sponsor
- Puerta de Hierro University Hospital
Record details
- Record id
cardio:ct-nct06712030- Content hash
3404440e025219c100f1aa6a5932ae33a8cc491c6b76c14f6c7b8cb6279955c4